Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
11:30am, Monday, 04'th May 2020
WALTHAM, Mass., May 04, 2020 -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central.
Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders
12:00am, Monday, 04'th May 2020
Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Sage Therapeutics: Looking For Positives Ahead Of Q1 Results
01:03pm, Thursday, 30'th Apr 2020
Earlier this month Sage announced it will cut 340 jobs - or 53% of its workforce - mainly from its Zulresso division to extend its cash runway. The failure of S
William Blair Reiterates Their Buy Rating on Neurocrine (NBIX)
11:38am, Thursday, 30'th Apr 2020
William Blair analyst Myles Minter reiterated a Buy rating on Neurocrine (NBIX) on April 27. The company's shares closed last Wednesday at $100.91.
William Blair Reiterates Their Buy Rating on Neurocrine (NBIX)
11:38am, Thursday, 30'th Apr 2020
William Blair analyst
Myles Minter
reiterated a
Buy
rating on Neurocrine (
NBIX
–
Research Report
) on April 27. The company’s shares closed last Wednesday at $100.91.
According to
TipRanks.com
,
Wall Street Analysts Are Neutral on Top Healthcare Picks
11:21am, Thursday, 30'th Apr 2020
Analysts fell to the sidelines weighing in on Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR) and Alkermes (ALKS) with neutral ratings,
H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)
11:16am, Thursday, 30'th Apr 2020
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Coherus Biosciences (CHRS), with a price target of $30.00. The
H.C. Wainwright Remains a Buy on Coherus Biosciences (CHRS)
11:15am, Thursday, 30'th Apr 2020
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Coherus Biosciences (CHRS – Research
Brazil's Minerva sees stronger U.S. demand for beef amid coronavirus closures
12:02pm, Wednesday, 29'th Apr 2020
Minerva SA, the largest beef exporter in South America, hopes to further boost foreign sales due to potentially scarce supplies in large producing nations like the United States, Chief Financial Offic
H.C. Wainwright Reaffirms Their Buy Rating on Amag Pharmaceuticals (AMAG)
11:19am, Wednesday, 29'th Apr 2020
In a report released today,
Douglas Tsao
from H.C. Wainwright maintained a
Buy
rating on Amag Pharmaceuticals (
AMAG
–
Research Report
), with a price target of
$9.00
. The company’s shares closed
H.C. Wainwright Sticks to Their Hold Rating for Radius Health (RDUS)
11:18am, Wednesday, 29'th Apr 2020
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Radius Health (RDUS), with a price target of $28.00. The
Cosmétiques : le sous-traitant Anjac s'empare de Roval
04:57pm, Monday, 27'th Apr 2020
Anjac, sous-traitant français dans la santé et les cosmétiques, s'empare d'un concurrent, Roval, quelques mois après s'être implanté aux Etats-Unis.
Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
12:30pm, Monday, 27'th Apr 2020
Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will rel
Theravance Biopharma (TBPH) Receives a Buy from H.C. Wainwright
03:26pm, Thursday, 23'rd Apr 2020
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Theravance Biopharma (TBPH), with a price target of $32.00. The
